Torrent Pharmaceuticals share pros and cons: branded generics quality franchise analysed for 2026. Germany market leadership, India chronic care dominance, 89x PE risk, and Mehta family discipline covered.

Why HAL share price keeps rising: LCA Tejas Mk1A Rs 48,000 crore order, 90,000+ crore order book, defence indigenisation, growing MRO revenue and India’s rising defence budget. Full analysis.

Why Cupid share price is rising: government contraceptive tenders, UNFPA and WHO export orders, branded consumer growth and capacity expansion. Full fundamental analysis of Cupid Ltd.

Mankind Pharma share pros and cons: India domestic pharma volume leader analysed for 2026. Rural doctor penetration, consumer brands, DPCO risks, and high PE valuation covered.

Lupin share pros and cons: India’s pharma value play at cheap 20x PE analysed for 2026. US respiratory pipeline, FDA compliance recovery, India branded generics, and OC segment competition covered.

Reliance Industries share pros and cons: India’s largest conglomerate analysed for 2026. Jio telecom, Reliance Retail, New Energy ambition, O2C risks, and conglomerate complexity covered.

Havells India share pros and cons: consumer electricals leader with cables, Lloyd AC, and switchgear analysed for 2026. India construction tailwind, PE risks, raw material sensitivity, and Lloyd competition covered.

ONGC share pros and cons: India’s oil PSU at ultra-cheap 6x PE and 5.5 percent yield analysed for 2026. Production leadership, Mumbai High decline, crude price risks, and KG basin opportunity covered.

Godrej Properties share pros and cons: India’s trusted pan-India real estate developer analysed for 2026. Godrej brand advantage, record bookings, multi-city execution risks, and high PE covered.

Vedanta share pros and cons: ultra-cheap 4x PE metals conglomerate analysed for 2026. Hindustan Zinc assets, 12.6 percent yield, UK parent debt governance risks, and demerger opportunity covered.